CEMI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CEMI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Chembio Diagnostics's 10-Year RORE % for the quarter that ended in Dec. 2022 was 11.16%.
The industry rank for Chembio Diagnostics's 10-Year RORE % or its related term are showing as below:
The historical data trend for Chembio Diagnostics's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chembio Diagnostics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
10-Year RORE % | Get a 7-Day Free Trial | 28.85 | 49.12 | 53.05 | 24.55 | 11.16 |
Chembio Diagnostics Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
10-Year RORE % | Get a 7-Day Free Trial | 24.55 | 24.18 | 18.86 | 19.56 | 11.16 |
For the Diagnostics & Research subindustry, Chembio Diagnostics's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Chembio Diagnostics's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Chembio Diagnostics's 10-Year RORE % falls into.
Chembio Diagnostics's 10-Year RORE % for the quarter that ended in Dec. 2022 is calculated as:
10-Year RORE % | = | ( Most Recent EPS (Diluted) | - | First Period EPS (Diluted) ) | / | ( Cumulative EPS (Diluted) for 10-year | - | Cumulative Dividends per Share for 10-year ) |
= | ( -0.72 | - | 0.05 ) | / | ( -6.9 | - | 0 ) | |
= | -0.77 | / | -6.9 | |||||
= | 11.16 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2022 and 10-year before.
Chembio Diagnostics (NAS:CEMI) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Thank you for viewing the detailed overview of Chembio Diagnostics's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Perceptive Credit Advisors, Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Leslie Teso-lichtman | director | C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788 |
Charles Caso | officer: See remarks | C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788 |
Paul Angelico | officer: See remarks | C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788 |
Lawrence J. Steenvoorden | officer: See remarks | C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788 |
David William Bespalko | director | 29 CEDAR DRIVE, ALLENDALE NJ 07401 |
David Acheson | director | C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788 |
Richard Eberly | officer: See Remarks | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
John Gary Potthoff | director | 6140 SPANISH OAKS CLUB BLVD., AUSTIN TX 78738 |
Javan Esfandiari | officer: Senior Vice President | 3661 HORSEBLOCK ROAD, MEDFORD NY 11763 |
Robert Passas | officer: See Remarks | 3661 HORSEBLOCK ROAD, MEDFORD NY 11763 |
Polan Mary Lake Ph D | director | STANFORD UNIVERSITY SCHOOL OF MEDICINE, 300 PASTAUR DR ROOM HH333, STANFORD CA 94305-5317 |
Neil A Goldman | officer: Executive VP and CFO | 3661 HORSEBLOCK RD, MEDFORD NY 11763 |
From GuruFocus
By PRNewswire PRNewswire • 02-02-2023
By GuruFocusNews GuruFocusNews • 06-16-2022
By GuruFocusNews GuruFocusNews • 06-25-2022
By PurpleRose PurpleRose • 08-16-2022
By PRNewswire PRNewswire • 04-20-2023
By PurpleRose PurpleRose • 07-21-2022
By Stock market mentor Stock market mentor • 01-31-2023
By PRNewswire PRNewswire • 02-01-2023
By PurpleRose PurpleRose • 07-15-2022
By PurpleRose PurpleRose • 07-13-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.